Cambridge Investment Research Advisors, Inc.
Position in GUTS — Fractyl Health, Inc.
CIK 1419186
FAIRFIELD, IA
Position in GUTS
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$50,816
+$21,504 QoQ
Shares Held
64,000
0.0% QoQ
Ownership
0.040%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#38
of 76 holders
Holding Since
Dec 2025
3 quarters on record
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cambridge Investment Research Advisors, Inc. holds $60,632,692 across 72 Biotechnology names. GUTS ranks #63 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
21,946 | $10,901,236 | |
| 2 | EXEL |
Exelixis, Inc.
|
82,212 | $4,473,154 | |
| 3 | NKTR |
Nektar Therapeutics
|
56,186 | $3,922,344 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
35,157 | $3,056,901 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
15,839 | $2,966,327 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,591 | $2,862,672 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
46,210 | $2,520,293 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
30,727 | $2,288,546 |
All Filings in GUTS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $50,816 | 64,000 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $29,312 | 64,000 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $140,800 | 64,000 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||